hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361862, orgStudyIdInfo id: WARD - Overtreatment, briefTitle: Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients?, acronym: WARD-OT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Rigshospitalet, Denmark, class: OTHER, collaborators name: Bispebjerg Hospital, descriptionModule briefSummary: This aim of this study is to investigate whether active alerts during CVSM result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the CVSM-group than standard of care (EWS) group., conditionsModule conditions: Cancer, conditions: Chronic Obstructive Pulmonary Disease, conditions: Surgery-Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 700, type: ESTIMATED, armsInterventionsModule interventions name: Active alarms from WARD software, outcomesModule primaryOutcomes measure: Frequency of patients having at least one of the following tests/treatments:, secondaryOutcomes measure: The frequency of individual treatments and diagnostics:, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Eske Kvanner Aasvang, status: RECRUITING, city: Copenhagen, zip: 2100, country: Denmark, contacts name: Eske K Aasvang, M.D., DMSci, role: CONTACT, phone: +4526232076, email: eske.kvanner.aasvang.01@regionh.dk, geoPoint lat: 55.67594, lon: 12.56553, hasResults: False
protocolSection identificationModule nctId: NCT06361849, orgStudyIdInfo id: 55013, briefTitle: TauTona Pneumoperitoneum Assist Device (TPAD), acronym: TPAD, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, collaborators name: TauTona Group, descriptionModule briefSummary: The purpose of this study is to assess the safety and ease of use of a trocar placement access device (TPAD) to assist with obtaining peritoneal access with a Veress needle, and for placing a primary trocar, during laparoscopic surgery., conditionsModule conditions: Laparoscopic Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Trocar Placement Assist Device (TPAD), outcomesModule primaryOutcomes measure: Surgeon satisfaction survey, secondaryOutcomes measure: Time required to obtain peritoneal access and place primary trocar during laparoscopic surgery, secondaryOutcomes measure: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford Hospital & Clinics, city: Palo Alto, state: California, zip: 94305, country: United States, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06361836, orgStudyIdInfo id: SBT777101-02, briefTitle: Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sonoma Biotherapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown., conditionsModule conditions: Hidradenitis Suppurativa, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Sequential escalating dose cohorts, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: SBT777101, outcomesModule primaryOutcomes measure: Incidence, nature, and severity of adverse events [Safety and Tolerability], primaryOutcomes measure: Incidence and nature of Dose Limiting Toxicities [DLTs], eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, status: RECRUITING, city: Boston, state: Massachusetts, zip: 02115, country: United States, contacts name: Oliva Gabriel, role: CONTACT, phone: 617-525-8250, email: ogabriel@bwh.harvard.edu, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06361823, orgStudyIdInfo id: IIH-Semaglutide, briefTitle: Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Capital Medical University, class: OTHER, descriptionModule briefSummary: This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension., conditionsModule conditions: Idiopathic Intracranial Hypertension, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The researchers are tasked with adhering to the protocol requirements when selecting participants, and consistently enrolling eligible patients who are then randomly assigned to either the experimental or control group in a 1:1 ratio. The randomization process is overseen by expert statisticians and executed by specialized clinical researchers in an independent manner., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide, interventions name: Low calorie diet, outcomesModule primaryOutcomes measure: Intracranial pressure, primaryOutcomes measure: Adverse reactions, secondaryOutcomes measure: Headache severity, secondaryOutcomes measure: Degree of papilledema, secondaryOutcomes measure: Perimetric mean deviation, secondaryOutcomes measure: Optic nerve sheath diameter, secondaryOutcomes measure: Body mass index, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361810, orgStudyIdInfo id: IRB00430008, briefTitle: PSMA Therapy and Immunotherapy in Kidney Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2030-07, completionDateStruct date: 2031-07, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, class: OTHER, collaborators name: Merck Sharp & Dohme LLC, collaborators name: Lantheus Medical Imaging, descriptionModule briefSummary: This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer., conditionsModule conditions: Metastatic Renal Cell Carcinoma, conditions: Metastatic Clear Cell Renal Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab, interventions name: 177Lu-PNT2002, interventions name: (F-18)-DCFPyL, outcomesModule primaryOutcomes measure: Safety assessed by the incidence of dose limiting toxicities., primaryOutcomes measure: Objective response rate by RECIST 1.1 criteria, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Safety as assessed by number of participants experiencing adverse events, secondaryOutcomes measure: Disease control rates, secondaryOutcomes measure: Duration of response to study therapy, secondaryOutcomes measure: Overall survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361797, orgStudyIdInfo id: IRB00415412, briefTitle: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2027-10, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, collaborators name: ON Foundation, descriptionModule briefSummary: Randomized controlled trial comparing benefits of varying amounts of proximal humerus-derived bone marrow aspirate and bone marrow concentrate in rotator cuff repair., conditionsModule conditions: Rotator Cuff Tears, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study is designed as a parallel group 1:1:1 randomized controlled trial., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Patients and research assistants collecting data will be unaware of assigned treatment until study completion., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Rotator cuff repair augmented with whole bone marrow, interventions name: Rotator cuff repair augmented with concentrated bone marrow, outcomesModule primaryOutcomes measure: Number of Rotator cuff re-tears as assessed by magnetic resonance imaging, secondaryOutcomes measure: American Shoulder and Elbow Surgeons Score, secondaryOutcomes measure: Visual Analogue Pain Score, secondaryOutcomes measure: Subjective Shoulder Value score, secondaryOutcomes measure: Comprehensive Shoulder Assessment, secondaryOutcomes measure: Revision surgery rate, secondaryOutcomes measure: Rate of oral and/or intra-articular corticosteroid required, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Johns Hopkins Howard County General Hospital, city: Columbia, state: Maryland, zip: 21230, country: United States, contacts name: Study Director, role: CONTACT, contacts name: Principal Investigator, role: CONTACT, geoPoint lat: 39.24038, lon: -76.83942, locations facility: Johns Hopkins Medicine - Green Spring Station, city: Lutherville, state: Maryland, zip: 21093, country: United States, contacts name: Matthew J Best, MD, role: CONTACT, phone: 443-997-2663, email: mbest8@jh.edu, contacts name: Uma Srikumaran, MD, MBA, MPH, role: CONTACT, phone: 410-546-1550, email: us@jhmi.edu, geoPoint lat: 39.42122, lon: -76.62608, hasResults: False
protocolSection identificationModule nctId: NCT06361784, orgStudyIdInfo id: INT216-23, secondaryIdInfos id: MFAG27480, type: OTHER_GRANT, domain: AIRC Foundation for Cancer Research in Italy, briefTitle: Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS), acronym: LM, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2029-03-29, completionDateStruct date: 2029-03-29, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, class: OTHER, collaborators name: Politecnico di Milano, descriptionModule briefSummary: The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy. Patients enrolled in the study will complete a set of extensive measures at the baseline, end of RT, and 9 months after treatment. Ultrasound exams, CT scans, pulmonary tests and wearable devices will assess functional and morphological parameters and the association with their variation and the dose delivered to the heart substructures and to the normal lung., conditionsModule conditions: Locally Advanced Lung Non-Small Cell Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, outcomesModule primaryOutcomes measure: Variation in eco-cardio and eco-vascular parameters after thoracic radiotherapy, secondaryOutcomes measure: Major adverse cardiac events post-RT, secondaryOutcomes measure: Increase in cardiac calcification after RT, otherOutcomes measure: Longitudinal variation of cardiopulmonary functional parameters, otherOutcomes measure: Texture variation in the heart substructures, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Istituto Nazionale dei Tumori, status: RECRUITING, city: Milan, zip: 20133, country: Italy, contacts name: Alessandro Cicchetti, PhD, role: CONTACT, phone: 0223903858, email: alessandro.cicchetti@istitutotumori.mi.it, contacts name: Chiara Casati, role: CONTACT, email: chiara.casati@istitutotumori.mi.it, contacts name: Alessandro Cicchetti, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06361758, orgStudyIdInfo id: B2023-326(2), briefTitle: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2027-05-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, collaborators name: Sun Yat-sen University, collaborators name: Eastern Hepatobiliary Surgery Hospital, descriptionModule briefSummary: This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cadonilimab+Lenvatinib, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR) per RECIST v1.1, secondaryOutcomes measure: Objective Response Rate (ORR) per mRECIST, secondaryOutcomes measure: Disease control Rate (DCR), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Progression-Free-Survival (PFS), secondaryOutcomes measure: Overall survival Overall survival (OS), secondaryOutcomes measure: Incidence of Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongshan Hospital, Fudan University, city: Shanghai, state: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, locations facility: Sun Yat-sen University Cancer Center), city: Guangzhou, country: China, contacts name: Li Xu, role: CONTACT, contacts name: Li Xu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, locations facility: Eastern Hepatobiliary Surgery Hospital, city: Shanghai, country: China, contacts name: Kui Wang, role: CONTACT, contacts name: Jun Xue, role: CONTACT, contacts name: Kui Wang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06361745, orgStudyIdInfo id: PG-005-6, briefTitle: Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: PersonGen BioTherapeutics (Suzhou) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: Main purpose:To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).Secondary purpose:To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID.To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects.To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects., conditionsModule conditions: Systemic Lupus Erythematosus, conditions: Idiopathic Inflammatory Myopathies, conditions: Systemic Sclerosis, conditions: IgG4 Related Disease, conditions: Primary Sjögren Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: UTAA09 injection, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: T cell injection targeting CD19 chimeric antigen receptor, outcomesModule primaryOutcomes measure: AE, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: CD19-positive cells, secondaryOutcomes measure: Disease remission/response/improvement rates, secondaryOutcomes measure: anti-CAR antibody, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: PersonGen.Anke Cellular Therapeutice Co., Ltd, status: RECRUITING, city: Hefei, country: China, contacts name: Huimin Meng, Doctor, role: CONTACT, phone: +86-18015580390, email: huimin.meng@persongen.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06361719, orgStudyIdInfo id: 2312INF, briefTitle: Efficacy of Two HMOs in Chinese Infants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2027-06, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Société des Produits Nestlé (SPN), class: INDUSTRY, descriptionModule briefSummary: This is a randomized, controlled, double-blind, intervention trial of healthy male and female term infants to evaluate the efficacy of the 2 HMOs on beneficially modulating the gut microbiota, gut maturation, gut barrier integrity, immune response, and other developmental outcomes in healthy Chinese infants. The trial consists of 2 randomized formula-fed groups, and a non-randomized breastfed reference group., conditionsModule conditions: Healthy Infants, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 262, type: ESTIMATED, armsInterventionsModule interventions name: Experimental Group (EG), interventions name: Control Group (CG), outcomesModule primaryOutcomes measure: Bifidobacteria abundance in fecal samples, secondaryOutcomes measure: Gut microbiota composition, secondaryOutcomes measure: Fecal metabolism, secondaryOutcomes measure: Fecal metabolism, secondaryOutcomes measure: Fecal markers of intestinal immune health, secondaryOutcomes measure: Fecal markers of gut barrier function, secondaryOutcomes measure: Fecal markers of gut barrier function, secondaryOutcomes measure: Fecal markers of gut barrier function, secondaryOutcomes measure: Fecal markers of inflammation, secondaryOutcomes measure: Fecal markers of inflammation, secondaryOutcomes measure: Fecal markers of inflammation, secondaryOutcomes measure: Stool patterns, secondaryOutcomes measure: Stool patterns, secondaryOutcomes measure: GI symptoms and behaviors, secondaryOutcomes measure: Immune competence, secondaryOutcomes measure: Infant sleep duration and night-time wakings per 24 hours, secondaryOutcomes measure: Infant Health Related Quality of Life, secondaryOutcomes measure: Growth, secondaryOutcomes measure: Growth, secondaryOutcomes measure: Growth, secondaryOutcomes measure: Growth, secondaryOutcomes measure: Growth, secondaryOutcomes measure: Physical Examination, secondaryOutcomes measure: Infant Illness, secondaryOutcomes measure: Infant illness, infections and medication usage, secondaryOutcomes measure: Medication use (type and duration), otherOutcomes measure: Formula feeding, otherOutcomes measure: Breastfeeding, otherOutcomes measure: Infant dietary pattern, eligibilityModule sex: ALL, minimumAge: 3 Days, maximumAge: 14 Days, stdAges: CHILD, contactsLocationsModule, hasResults: False